期刊文献+

沙利度胺治疗克罗恩病的研究进展 被引量:2

Progress in Study on Thalidomide for Treatment of Crohn's Disease
下载PDF
导出
摘要 克罗恩病(CD)是一种慢性非特异性肠道炎症性疾病,其发病机制尚未完全明确。近年来随着对肿瘤坏死因子(TNF)-α在CD发病机制中的认识,针对TNF-α的靶向治疗成为关注热点。沙利度胺因具有抑制TNF-α的特性,在CD尤其是难治性CD的治疗中起一定作用。本文就沙利度胺治疗CD的研究进展作一综述。 Crohn's disease (CD) is a chronic non-specific intestinal inflammatory disease and its pathogenesis has not yet been fully clarified. In recent years, with the understanding of involvement of tumor necrosis factor (TNF)-α in the pathogenesis of CD, much attention has been paid on the TNF-α targeted therapy. Thalidomide has anti-TNF-α effect and has been used in the treatment of CD, especially refractory CD. This article reviewed the progress in study on thalidomide for the treatment of CD.
出处 《胃肠病学》 2012年第9期570-572,共3页 Chinese Journal of Gastroenterology
关键词 CROHN病 沙利度胺 英夫利昔 治疗 Crohn Disease Thalidomide Infliximab Therapy
  • 相关文献

参考文献3

二级参考文献31

  • 1肖瑛,许元富,周圆,杨纯正.靶向肿瘤坏死因子的炎性肠病治疗研究进展[J].世界临床药物,2004,25(11):683-687. 被引量:4
  • 2Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 pa- tients. Ann Surg 1991; 214: 230-238; discussion 238-240. 被引量:1
  • 3MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma pro- duction measured at the single cell level in normal and in- flamed human intestine. Clin Exp Immunol 1990; 81:301-305. 被引量:1
  • 4van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135. 被引量:1
  • 5Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001; 345:1098-1104. 被引量:1
  • 6Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363:1802-1811. 被引量:1
  • 7Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Tha- lidomide selectively inhibits tumor necrosis factor alpha pro- duction by stimulated human monocytes. J Exp Med 1991; 173:699-703. 被引量:1
  • 8Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn' s disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277. 被引量:1
  • 9Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117:1278-1287. 被引量:1
  • 10Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892. 被引量:1

共引文献14

同被引文献13

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部